Messenger RNA (mRNA) combination vaccines for seasonal influenza and COVID-19 are currently in advanced clinical development. These mRNA combination vaccines aim to simplify immunization by targeting two major respiratory threats with a single dose. Consequently, healthcare payers and providers must understand how to measure the total value of these products beyond simple cost-effectiveness. A new study recently introduced a comprehensive taxonomy to capture this value from a broad societal perspective.

Key Elements of the mRNA Combination Vaccines Taxonomy

The taxonomy distinguishes between narrow health-related values and broader societal benefits. Furthermore, it highlights novel values like improved strain selection, which significantly raises vaccine efficacy. Additionally, the study found that combined shots improve compliance with vaccine schedules. This increased uptake translates to reduced treatment costs and better health for both patients and caregivers. Moreover, reducing the total number of injections required lowers adverse event rates and clinical anxiety.

Implications for Global Health Policy

Traditional valuation frameworks often focus only on direct medical savings. However, the new taxonomy suggests that mRNA combination vaccines provide significant process utilities and increase health equity. By reducing logistical hurdles, these vaccines can reach vulnerable populations more effectively. In addition, the framework accounts for productivity gains and research spillovers. Therefore, national recommendation bodies should adopt this holistic approach when evaluating future vaccine funding and coverage decisions.

Frequently Asked Questions

1. What is the primary benefit of mRNA combination vaccines?

These vaccines combine protection against influenza and COVID-19 into one shot, enhancing patient convenience and improving adherence to immunization schedules.

2. How does the new taxonomy assist healthcare payers?

It provides a robust framework to assess both traditional health outcomes and broader societal values, such as workplace productivity and healthcare equity, ensuring better value-for-money assessments.

3. Why is strain selection considered a value element?

The mRNA platform allows for more rapid and accurate matching to circulating virus strains. This improved selection increases the overall efficacy of the vaccine, leading to better clinical outcomes during respiratory seasons.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional endorsement. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Sevilla JP et al. The full value of mRNA seasonal influenza and endemic-stage COVID-19 combination vaccines: a taxonomy. J Med Econ. 2026 Dec undefined. doi: 10.1080/13696998.2026.2638676. PMID: 41843918.


2. Buck PO, Gomes DA, Beck E, et al. New Vaccine Platforms—Novel Dimensions of Economic and Societal Value and Their Measurement. Vaccines. 2024;12(2):189.


3. Moderna. The Potential Impact of Combination Vaccines on Public Health. June 2024. Available at modernatx.com.